Neuronetics to Present at the Piper Sandler 36th Annual Healthcare Conference
Neuronetics to Present at the Piper Sandler 36th Annual Healthcare Conference
Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is redefining patient and physician expectations with its NeuroStar Advanced Therapy for Mental Health. NeuroStar is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication hasn't helped. The NeuroStar Advanced Therapy System is cleared by the U.S. Food and Drug Administration (the "FDA") for adults with MDD, as an adjunct for adults with obsessive-compulsive disorder, and to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression), and as a first line adjunct for the treatment of MDD in adolescent patients aged 15-21. NeuroStar Advanced Therapy is the leading TMS treatment for MDD in adults with more than 6.9 million treatments delivered. NeuroStar is backed by the largest clinical data set of any TMS treatment system for depression, including the world's largest depression outcomes registry. Neuronetics is committed to transforming lives by offering an exceptional treatment that produces extraordinary results. For safety and prescribing information, NeuroStar.com.MALVERN, Pa., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced that the management team will present at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024. The Company is scheduled to present at 2:30pm Eastern Time the same day via webcast.
宾夕法尼亚州马尔文，2024年11月20日（GLOBE NEWSWIRE）——专注于设计、开发和营销改善神经健康障碍患者生活质量的产品的医疗技术公司Neuronetics, Inc.（纳斯达克股票代码：STIM）今天宣布，管理团队将于2024年12月4日星期三出席派珀·桑德勒第36届年度医疗保健会议。该公司计划于美国东部时间当天下午 2:30 通过网络直播亮相。
A live audio webcast of the presentation will be available online at the investor relations page of the Company's website at ir.neuronetics.com.
该演讲的网络直播将在公司网站ir.neuronetics.com的投资者关系页面上在线播出。
About Neuronetics
关于 Neuronetics
Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is redefining patient and physician expectations with its NeuroStar Advanced Therapy for Mental Health. NeuroStar is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication hasn't helped. The NeuroStar Advanced Therapy System is cleared by the U.S. Food and Drug Administration (the "FDA") for adults with MDD, as an adjunct for adults with obsessive-compulsive disorder, and to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression), and as a first line adjunct for the treatment of MDD in adolescent patients aged 15-21. NeuroStar Advanced Therapy is the leading TMS treatment for MDD in adults with more than 6.9 million treatments delivered. NeuroStar is backed by the largest clinical data set of any TMS treatment system for depression, including the world's largest depression outcomes registry. Neuronetics is committed to transforming lives by offering an exceptional treatment that produces extraordinary results. For safety and prescribing information, NeuroStar.com.
Neuronetics, Inc. 认为，心理健康与身体健康同样重要。作为神经科学领域的全球领导者，Neuronetics正在通过其NeuroStar心理健康高级疗法重新定义患者和医生的期望。NeuroStar是一种非药物、无创的治疗方法，在传统药物无济于事的情况下，它可以改善患有神经健康疾病的人的生活质量。NeuroStar 高级治疗系统已获得美国食品药品监督管理局（“FDA”）的批准，适用于成人 MDD，作为强迫症成人的辅助药物，可减轻可能出现合并焦虑症状（焦虑抑郁症）的成年耐多糖患者的焦虑症状，并作为治疗15-21岁青少年患者MDD的一线辅助药物。NeuroStar Advanced Therapy是成人MDD的领先TMS治疗方法，已提供超过690万次治疗。NeuroStar由所有TMS抑郁症治疗系统中最大的临床数据集支持，包括世界上最大的抑郁症预后登记库。Neuronetics致力于通过提供可产生非凡效果的卓越治疗来改变生活。有关安全和处方信息，请访问 Neurostar.com。
Investor Contact:
投资者联系人：
Mike Vallie or Mark Klausner
ICR Healthcare
443-213-0499
ir@neuronetics.com
迈克·瓦利或马克·克劳斯纳
ICR 医疗保健
443-213-0499
ir@neuronetics.com
Media Contact:
媒体联系人：
EvolveMKD
646-517-4220
NeuroStar@evolvemkd.com
EvolveMKD
646-517-4220
NeuroStar@evolvemkd.com
